Crescita Therapeutics (Crescita Therapeutics) 5-Year EBITDA Growth Rate : -47.70% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics 5-Year EBITDA Growth Rate?

Crescita Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $0.02.

During the past 12 months, Crescita Therapeutics's average EBITDA Per Share Growth Rate was -96.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -69.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -47.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Crescita Therapeutics was 20.10% per year. The lowest was -69.70% per year. And the median was -32.50% per year.

Competitive Comparison of Crescita Therapeutics's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's 5-Year EBITDA Growth Rate falls into.

Crescita Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Crescita Therapeutics (OTCPK:CRRTF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Crescita Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (Crescita Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CTX:Canada

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.